Table V.
Twenty-four week change in asthma symptoms, lung function, and sinus symptoms in adults (ages 18 and older) treated with mometasone versus placebo.
N | Change from randomization (SE) |
Difference in change from randomization (95% CI) |
P-value | |||||
---|---|---|---|---|---|---|---|---|
Mometasone | Placebo | Mometasone - Placebo | ||||||
Asthma Symptom Utility Index | 193 | 0.09 (0.01) | 0.03 (0.02) | 0.06 (0.01 ,0.11) | < 0.01 | |||
Marks asthma quality of life questionnaire | 192 | -5.26 (1.11) | -5.48 (1.06) | 0.22 (-2.82 ,3.26) | 0.89 | |||
Lung function | ||||||||
Pre-bronchodilator FEV1 (% predicted) | 193 | -1.40 (1.07) | 0.51 (0.97) | -1.91 (-4.76 ,0.94) | 0.18 | |||
Pre-bronchodilator FVC (% predicted) | 193 | -1.27 (0.95) | 0.06 (0.85) | -1.33 (-3.85 ,1.19) | 0.30 | |||
FEV1/FVC | 193 | -0.001 (0.004) | 0.004 (0.004) | -0.005 (-0.017 ,0.008) | 0.43 | |||
FeNO (ppb)* | 183 | -0.08 (1.98) | -0.02 (2.96) | -0.06 (-7.08, 6.96) | 0.99 | |||
Sinus symptoms | ||||||||
Sinus Symptom Score | 194 | -9.46 (1.18) | -5.64 (1.24) | -3.82 (-7.19 ,-0.45) | 0.03 | |||
SN-22 | 193 | -11.2 (1.86) | -6.37 (1.75) | -4.83 (-9.86 ,0.21) | 0.06 |
FeNO was measured at baseline and at 24 weeks.
N = number of participants evaluable at 24 weeks; CI = confidence interval.